Skip to content

Gross margin at other companies

Amgen logo
AmgenAMGN
68.3%+5.3pp
Agios Pharmaceuticals logo
Agios PharmaceuticalsAGIO
90%+2.5pp
Nuvation Bio logo
Nuvation BioNUVB
54.3%+39.5pp
Zevra Therapeutics, Inc. logo
Zevra Therapeutics, Inc.ZVRA
86.1%+7.2pp
Gyre Therapeutics, Inc. logo
Gyre Therapeutics, Inc.GYRE
95.1%-1.1pp
Eton Pharmaceuticals, Inc. logo
Eton Pharmaceuticals, Inc.ETON
54.8%-3.7pp

Other financials

Income statement

See full
Revenue$58.8M+10.3%
Gross profit$54.2M+10.8%
Operating income$11.9M-7.0%
Net income$8.7M-24.4%
EPS (diluted)$0.44-30.2%

Balance sheet

See full
Cash & equivalents$24.5M-46.6%
Total debt$68.4M+5,079%
Total equity$399.9M+2,054%
Total assets$504.6M+187%

Cash flow

See full
Operating cash flow$2.7M+405%
CapEx$73.0K
Free cash flow-$22.0M

Valuation

See full
Market cap$684.39M+102%
Enterprise value$728.29M+148%
P/E1.9×-7.2×
P/S2.3×+0.6×

Profitability

See full
Operating margin41.6%+19.9pp
Net margin121.5%+103pp
FCF margin-61.7%

Returns & leverage

See full
Return on equity174.1%
Debt / equity0.2×+0.1×
Current ratio2.6×+0.4×

Where this comes from

Calculated from Rigel Pharmaceuticals’s reported figures.

Based on trailing twelve months.

The official record: Rigel Pharmaceuticals’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →

Ask your AI about Rigel Pharmaceuticals's gross margin.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Rigel Pharmaceuticals's gross margin?
Rigel Pharmaceuticals (RIGL) reported gross margin of 93.4% in Q1 2026.
How has Rigel Pharmaceuticals's gross margin changed year-over-year?
Rigel Pharmaceuticals's gross margin increased by 4.2% year-over-year, from 89.6% to 93.4%.
What is the long-term trend for Rigel Pharmaceuticals's gross margin?
Over 5 years (2020 to 2025), Rigel Pharmaceuticals's gross margin has grown at a -1.2% compound annual growth rate (CAGR), from 99.2% to 93.3%.
What does gross margin mean?
Gross profit (revenue minus cost of revenue) as a percentage of revenue, on a trailing-twelve-month basis. Measures how much of each sales dollar survives the direct cost of producing the goods or services sold.